Genelux Total Current Liabilities from 2010 to 2024
| GNLX Stock | 2.69 0.20 8.03% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 6.6 M | Current Value 6.2 M | Quarterly Volatility 5.9 M |
Check Genelux Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genelux Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 883.5 K, Interest Expense of 4.2 M or Other Operating Expenses of 16.8 M, as well as many indicators such as Price To Sales Ratio of 2.1 K, Dividend Yield of 0.0 or PTB Ratio of 18.45. Genelux financial statements analysis is a perfect complement when working with Genelux Common Valuation or Volatility modules.
Genelux | Total Current Liabilities |
Latest Genelux Common's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Genelux Common over the last few years. Total Current Liabilities is an item on Genelux Common balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Genelux Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Genelux Common's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genelux Common's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Genelux Total Current Liabilities Regression Statistics
| Arithmetic Mean | 15,242,820 | |
| Geometric Mean | 14,244,354 | |
| Coefficient Of Variation | 38.45 | |
| Mean Deviation | 3,149,781 | |
| Median | 14,726,000 | |
| Standard Deviation | 5,860,615 | |
| Sample Variance | 34.3T | |
| Range | 25.4M | |
| R-Value | 0.02 | |
| Mean Square Error | 37T | |
| R-Squared | 0.0003 | |
| Significance | 0.95 | |
| Slope | 22,497 | |
| Total Sum of Squares | 480.9T |
Genelux Total Current Liabilities History
About Genelux Common Financial Statements
Genelux Common investors use historical fundamental indicators, such as Genelux Common's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Genelux Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 6.6 M | 6.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.